Skip to main content
Top
Published in: International Urology and Nephrology 4/2024

01-12-2023 | Urolithiasis | Urology - Review

Systematic review of the risk of urolithiasis following parathyroidectomy in patients with primary hyperparathyroidism

Authors: Xingmu Wang, Ge Shi, Gangfeng Li, Guiliang Tang

Published in: International Urology and Nephrology | Issue 4/2024

Login to get access

Abstract

Objective

Parathyroidectomy (PTX) is the conclusive therapy for primary hyperparathyroidism (PHPT), but its effect on the risk of urolithiasis is inconclusive. We comprehensively reviewed the currently available research to investigate the impact of PTX on the likelihood of urolithiasis among individuals suffering PHPT.

Methods

Internet-based articles in English language released on Cochrane, PubMed, Scopus, Web of knowledge, and Embase up to September, 2023 were comprehensively reviewed. Each publication in contrast to the incidence, occurrence, or recurrence of urolithiasis after PTX versus medical treatment in PHPT patients was included. The outcome with pooled relative risks (RRs) and corresponding 95% confidence intervals (CIs) was examined employing DerSimonian and Laird’s model of random effects. To determine the range of the real effect size of a future study in 95% of all populations, a prediction interval (PI) was also established.

Results

Finally, ten studies involving 74,190 patients were included. Results from randomized-controlled trials (RCTs) and observational studies (OSs) both revealed that PTX did not substantially lessen the vulnerability of urolithiasis among individuals with PHPT (RCTs: pooled relative risk [RR] 0.42, 95%CI 0.13–1.41, p = 0.163; OSs: pooled RR 1.37, 95%CI 0.96 to 1.97, p = 0.084). The PI (RCT: 0.03 to 5.96; OSs: 0.44–4.20) containing 1.0 suggested the possibility of consistent results in future studies. Subgroup and sensitivity analyses supported the above findings, and no evidence showed publication bias.

Conclusion

Our analysis from the available RCTs or OSs did not give adequate or exact proof that the average effect of PTX lowers the incidence of urolithiasis among PHPT persons based on the random-effects model. Future research shall take into account the common effect of PTX as well as the prerequisites of preventive stone procedures, which will further help us assess the effectiveness of PTX in reducing kidney calculus comorbidity and develop techniques to avoid stone sequelae in these individuals.
Appendix
Available only for authorised users
Literature
2.
go back to reference Zhu CY, Sturgeon C, Yeh MW (2020) Diagnosis and management of primary hyperparathyroidism. JAMA 323(12):1186–1187CrossRefPubMed Zhu CY, Sturgeon C, Yeh MW (2020) Diagnosis and management of primary hyperparathyroidism. JAMA 323(12):1186–1187CrossRefPubMed
3.
go back to reference Silverberg SJ et al (2014) Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3580–3594CrossRefPubMedPubMedCentral Silverberg SJ et al (2014) Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99(10):3580–3594CrossRefPubMedPubMedCentral
4.
go back to reference Rubin MR et al (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88(3):1174–1178CrossRefPubMed Rubin MR et al (2003) Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88(3):1174–1178CrossRefPubMed
5.
go back to reference Nordin BE et al (2004) Effect of age on calcium absorption in postmenopausal women. Am J Clin Nutr 80(4):998–1002CrossRefPubMed Nordin BE et al (2004) Effect of age on calcium absorption in postmenopausal women. Am J Clin Nutr 80(4):998–1002CrossRefPubMed
7.
go back to reference Yeh MW, Ituarte PH, Zhou HC et al (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98(3):1122–1129CrossRefPubMedPubMedCentral Yeh MW, Ituarte PH, Zhou HC et al (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98(3):1122–1129CrossRefPubMedPubMedCentral
8.
go back to reference Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 73:1–7CrossRefPubMed Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 73:1–7CrossRefPubMed
9.
go back to reference Minisola S, Arnold A, Belaya Z et al (2022) Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res 37(11):2315–2329CrossRefPubMed Minisola S, Arnold A, Belaya Z et al (2022) Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res 37(11):2315–2329CrossRefPubMed
11.
go back to reference Yu N, Donnan PT, Murphy MJ, Leese GP (2009) Epidemiology of primary hyperparathyroidism in Tayside, Scotland. UK Clin Endocrinol (Oxf) 71(4):485–493CrossRefPubMed Yu N, Donnan PT, Murphy MJ, Leese GP (2009) Epidemiology of primary hyperparathyroidism in Tayside, Scotland. UK Clin Endocrinol (Oxf) 71(4):485–493CrossRefPubMed
12.
go back to reference Collier A, Portelli M, Ghosh S, Nowell S, Clark D (2017) Primary hyperparathyroidism: Increasing prevalence, social deprivation, and surgery. Endocr Res 42(1):31–35CrossRefPubMed Collier A, Portelli M, Ghosh S, Nowell S, Clark D (2017) Primary hyperparathyroidism: Increasing prevalence, social deprivation, and surgery. Endocr Res 42(1):31–35CrossRefPubMed
13.
go back to reference Soto-Pedre E, Newey PJ, Leese GP (2023) Stable incidence and increasing prevalence of primary hyperparathyroidism in a population-based study in Scotland. J Clin Endocrinol Metab 108:e1117CrossRefPubMedPubMedCentral Soto-Pedre E, Newey PJ, Leese GP (2023) Stable incidence and increasing prevalence of primary hyperparathyroidism in a population-based study in Scotland. J Clin Endocrinol Metab 108:e1117CrossRefPubMedPubMedCentral
14.
go back to reference Yan ST, Tian H, Li CL et al (2007) A preliminary survey of primary hyperparathyroidism in middle-aged and elderly Beijing Chinese. Zhonghua Nei Ke Za Zhi 46(8):651–653PubMed Yan ST, Tian H, Li CL et al (2007) A preliminary survey of primary hyperparathyroidism in middle-aged and elderly Beijing Chinese. Zhonghua Nei Ke Za Zhi 46(8):651–653PubMed
15.
go back to reference Wermers RA (2023) The Incidence of Primary Hyperparathyroidism in the Current Era: Have We Finally Reached a Steady State. J Clin Endocrinol Metab 108:e1749CrossRefPubMedPubMedCentral Wermers RA (2023) The Incidence of Primary Hyperparathyroidism in the Current Era: Have We Finally Reached a Steady State. J Clin Endocrinol Metab 108:e1749CrossRefPubMedPubMedCentral
16.
go back to reference Castellano E et al (2017) Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status. J Clin Endocrinol Metab 102(11):4148–4152CrossRefPubMed Castellano E et al (2017) Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status. J Clin Endocrinol Metab 102(11):4148–4152CrossRefPubMed
17.
go back to reference Arya AK et al (2021) Differences in Primary Hyperparathyroidism Between Pre- and Postmenopausal Women in India. Endocr Pract 27(7):710–715MathSciNetCrossRefPubMed Arya AK et al (2021) Differences in Primary Hyperparathyroidism Between Pre- and Postmenopausal Women in India. Endocr Pract 27(7):710–715MathSciNetCrossRefPubMed
18.
go back to reference Clifton-Bligh PB, Nery ML, Supramaniam R et al (2015) Mortality associated with primary hyperparathyroidism. Bone 74:121–124CrossRefPubMed Clifton-Bligh PB, Nery ML, Supramaniam R et al (2015) Mortality associated with primary hyperparathyroidism. Bone 74:121–124CrossRefPubMed
19.
go back to reference Lui MS, Fisher JC, Underwood HJ, Patel KN, Ogilvie JB (2022) Stones left unturned: Missed opportunities to diagnose primary hyperparathyroidism in patients with nephrolithiasis. Surgery 171(1):23–28CrossRefPubMed Lui MS, Fisher JC, Underwood HJ, Patel KN, Ogilvie JB (2022) Stones left unturned: Missed opportunities to diagnose primary hyperparathyroidism in patients with nephrolithiasis. Surgery 171(1):23–28CrossRefPubMed
22.
go back to reference Khan AA, Hanley DA, Rizzoli R et al (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28(1):1–19CrossRefPubMed Khan AA, Hanley DA, Rizzoli R et al (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28(1):1–19CrossRefPubMed
24.
go back to reference Pak CY (1979) Effect of parathyroidectomy on crystallization of calcium salts in urine of patients with primary hyperparathyroidism. Invest Urol 17:146–148PubMed Pak CY (1979) Effect of parathyroidectomy on crystallization of calcium salts in urine of patients with primary hyperparathyroidism. Invest Urol 17:146–148PubMed
29.
33.
go back to reference Hung KC et al (2022) Association of preoperative vitamin D deficiency with the risk of postoperative delirium and cognitive dysfunction: A meta-analysis. J Clin Anesth 79:110681CrossRefPubMed Hung KC et al (2022) Association of preoperative vitamin D deficiency with the risk of postoperative delirium and cognitive dysfunction: A meta-analysis. J Clin Anesth 79:110681CrossRefPubMed
34.
go back to reference Lundstam K, Heck A, Mollerup C et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100(4):1359–1367CrossRefPubMed Lundstam K, Heck A, Mollerup C et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100(4):1359–1367CrossRefPubMed
35.
go back to reference Pretorius M, Lundstam K, Heck A et al (2022) Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation. Ann Intern Med 175(6):812–819CrossRefPubMed Pretorius M, Lundstam K, Heck A et al (2022) Mortality and Morbidity in Mild Primary Hyperparathyroidism: Results From a 10-Year Prospective Randomized Controlled Trial of Parathyroidectomy Versus Observation. Ann Intern Med 175(6):812–819CrossRefPubMed
36.
go back to reference Rao DS, Wallace EA, Antonelli RF et al (2003) Forearm bone density in primary hyperparathyroidism: long-term follow-up with and without parathyroidectomy. Clin Endocrinol (Oxf) 58(3):348–354CrossRefPubMed Rao DS, Wallace EA, Antonelli RF et al (2003) Forearm bone density in primary hyperparathyroidism: long-term follow-up with and without parathyroidectomy. Clin Endocrinol (Oxf) 58(3):348–354CrossRefPubMed
37.
go back to reference Ambrogini E et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92(8):3114–3121CrossRefPubMed Ambrogini E et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92(8):3114–3121CrossRefPubMed
38.
go back to reference Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89(11):5415–5422CrossRefPubMed Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89(11):5415–5422CrossRefPubMed
39.
go back to reference Posen S, Clifton-Bligh P, Reeve TS, Wagstaffe C, Wilkinson M (1985) Is parathyroidectomy of benefit in primary hyperparathyroidism. Q J Med 54(215):241–251PubMed Posen S, Clifton-Bligh P, Reeve TS, Wagstaffe C, Wilkinson M (1985) Is parathyroidectomy of benefit in primary hyperparathyroidism. Q J Med 54(215):241–251PubMed
40.
go back to reference Vestergaard P, Mosekilde L (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327(7414):530–534CrossRefPubMedPubMedCentral Vestergaard P, Mosekilde L (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ 327(7414):530–534CrossRefPubMedPubMedCentral
41.
go back to reference Seib CD et al (2021) Association of Parathyroidectomy With 5-Year Clinically Significant Kidney Stone Events in Patients With Primary Hyperparathyroidism. Endocr Pract 27(9):948–955CrossRefPubMed Seib CD et al (2021) Association of Parathyroidectomy With 5-Year Clinically Significant Kidney Stone Events in Patients With Primary Hyperparathyroidism. Endocr Pract 27(9):948–955CrossRefPubMed
42.
go back to reference Seib CD, Ganesan C, Arnow KD et al (2022) Kidney Stone Events Following Parathyroidectomy vs Nonoperative Management for Primary Hyperparathyroidism. J Clin Endocrinol Metab 107(7):e2801–e2811CrossRefPubMedPubMedCentral Seib CD, Ganesan C, Arnow KD et al (2022) Kidney Stone Events Following Parathyroidectomy vs Nonoperative Management for Primary Hyperparathyroidism. J Clin Endocrinol Metab 107(7):e2801–e2811CrossRefPubMedPubMedCentral
43.
go back to reference Huang SY et al (2022) Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea. Surgery 171(1):29-34CrossRef Huang SY et al (2022) Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea. Surgery 171(1):29-34CrossRef
44.
go back to reference Axelsson KF et al (2022) Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Netw Open 5(6):e2215396CrossRefPubMedPubMedCentral Axelsson KF et al (2022) Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Netw Open 5(6):e2215396CrossRefPubMedPubMedCentral
45.
go back to reference Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96(8):2377–2385CrossRefPubMed Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96(8):2377–2385CrossRefPubMed
46.
go back to reference Bilezikian JP et al (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94(2):335–339CrossRefPubMedPubMedCentral Bilezikian JP et al (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94(2):335–339CrossRefPubMedPubMedCentral
47.
go back to reference Mollerup CL, Lindewald H (1999) Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg 23(2):173–175 (discussion 176)CrossRefPubMed Mollerup CL, Lindewald H (1999) Renal stones and primary hyperparathyroidism: natural history of renal stone disease after successful parathyroidectomy. World J Surg 23(2):173–175 (discussion 176)CrossRefPubMed
Metadata
Title
Systematic review of the risk of urolithiasis following parathyroidectomy in patients with primary hyperparathyroidism
Authors
Xingmu Wang
Ge Shi
Gangfeng Li
Guiliang Tang
Publication date
01-12-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03882-w

Other articles of this Issue 4/2024

International Urology and Nephrology 4/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.